BMY: BioNTech and Bristol Myers Squibb Report Encouraging Phase 2 Pumitamig Data in Advanced NSCLC

What happened

Bristol Myers Squibb and BioNTech released company‑reported Phase 2 clinical data for pumitamig in advanced NSCLC in patients who progressed after immunotherapy plus chemotherapy. The announcement describes efficacy results and a manageable safety profile. The item is listed in SMC’s current news digest as a confirmed company data release (press release link in the digest).

Sources: S1

Why it matters

This is a company‑level clinical catalyst for BMY: SMC flags the item as confirmed news with medium catalyst strength and BMY appears as a news runner. market data shows after‑hours BMY at $62.01 (+0.85%) with elevated relative volume (relative volume 14.48) and ~3.06M shares traded in the market data — evidence of trader attention. Traders should read the issuer release for the detailed endpoints, patient counts and safety breakdown before sizing exposure.

Sources: S1

What remains uncertain

• SMC digest records the issuer press release but the supplied market data do not include numeric efficacy endpoints (response rates, survival data), patient counts or detailed safety tables — consult the full company release for those specifics.
• Market figures (price, relative volume, volume) are from the SMC after‑hours market data and may change as trading continues; use live market quotes for execution decisions.